trending Market Intelligence /marketintelligence/en/news-insights/trending/4abi7bmus7hocauxdht-0a2 content esgSubNav
In This List

Endocyte raises $80.6M via common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Endocyte raises $80.6M via common stock offering

Endocyte Inc. closed a public offering of 20,535,714 shares, raising approximately $80.6 million in net proceeds.

The West Lafayette, Ind.-based biopharmaceutical company will use the funds to advance its product pipeline which includes Lu-PSMA-617 for the treatment of prostate cancer which is resistant to medical or surgical treatments and has spread to other parts of the body.

Jefferies LLC, Wells Fargo Securities LLC and Deutsche Bank Securities Inc. acted as joint book-running managers for the offering, with Wedbush Securities Inc. as co-lead manager.